ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0696

Impact of Renal Replacement Therapy Modality on Prognosis of SARS-CoV2 Infection

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Lombardi, Yannis, Hopital Tenon, Paris, Île-de-France, France
  • Fessi, Hafedh, Hopital Tenon, Paris, Île-de-France, France
  • François, Hélène, Hopital Tenon, Paris, Île-de-France, France
  • Michel, Pierre Antoine, Hopital Tenon, Paris, Île-de-France, France
  • Petit-Hoang, Camille, Hopital Tenon, Paris, Île-de-France, France
  • Rondeau, Eric, Hopital Tenon, Paris, Île-de-France, France
Background

Prognosis of SARS-CoV2 infection among patients with Chronic Kidney Disease (CKD) is poorly known. In particular, the impact of renal replacement therapy (RRT) modality on prognosis is undetermined. Patients with kidney transplant exhibit treatment-induced immunodepression, while patients on dialysis are usually older and exhibit higher frailty. We aim to determine the impact of RRT modality on the prognosis of SARS-CoV2 infection among patient with advanced CKD.

Methods

We conducted a retrospective cohort study using our institution’s Clinical Data Warehouse. Health records of all patients with at least one hozpitalization or consultation in our nephrology department were screened based on ICD-10 codes. Inclusion criteria were: hospitalization in any of our institution’s hospitals for SARS-CoV2 infection (national Public Health agency criteria). Patients were divided into two groups: «active kidney transplant» and «dialysis». A Cox model stratifying on age and medical history of coronary artery disease was used to determine adjusted Hazard Ratio (HR) for death or intensive care unit (ICU) admission.

Results

We included 72 patients: 47 in the «transplant» group and 25 in the «dialysis» group. First hospitalization was on 20/02/28 and last hospitalization on 20/05/19. Median follow-up was 21.5 days. Death or ICU admission occurred in 21 (29%) patients («transplant» group: 15 (32%), «dialysis» group: 6 (24%), p=0.45). In multivariate analysis, adjusted HR for death or ICU admission was 1.70 [95%CI:0.59–4.86] for transplant vs. dialysis (p=0.32).

Conclusion

In our study, among patients hospitalized for SARS-CoV2 infection, no significant difference in risk for ICU hospitalization or death was found between CKD patients on dialysis or with active kidney transplant. A trend for higher risk was noted among patients with active kidney transplant. Further studies are required to confirm those findings.